SIA
PACB icon

SkyView Investment Advisors’s Pacific Biosciences PACB Stock Holding History

SkyView Investment Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,000
Closed -$200K – 713
2023
Q2 		$200K Hold
15,000
– – 0.05% 359
2023
Q1 		$174K Buy
+15,000
New +$149K 0.04% 355

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

SkyView Investment Advisors's PACB Position: Q3 2023 in Review

SkyView Investment Advisors sold out of Pacific Biosciences (PACB) in Q3 2023, closing a stake of 15,000 shares — an estimated $200K sold.

SkyView Investment Advisors first reported a position in PACB in Q1 2023 and held it in 2 quarters. The position peaked at $200K in Q2 2023. 274 funds tracked by Wall St. Rank hold PACB as of Q3 2023.

  • SkyView Investment Advisors reported no remaining Pacific Biosciences position as of Q3 2023 after selling out during the quarter.
  • SkyView Investment Advisors sold 15,000 Pacific Biosciences shares in Q3 2023, an estimated $200K.
  • SkyView Investment Advisors first reported a position in Pacific Biosciences in Q1 2023 and held it in 2 quarters.
  • SkyView Investment Advisors's Pacific Biosciences position peaked at $200K in Q2 2023.
  • 274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2023.

Based on SkyView Investment Advisors's 13F filing for Q3 2023, filed 17 Nov 2023.